Saruparib (AZD5305) Clinical Trials

3 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: AZD5305, Darolutamide is also known as Nubeqa, Saruparib

Pipeline

Phase 1: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

AstraZeneca3

Indications

Cancer3
Locally Advanced or Metastatic Solid Tumor1
Lung Squamous Cell Carcinoma1
Lung Adenocarcinoma1
Advanced Breast Cancer1

Other1 trial

AZD5305 hADME in Patients With Advanced Solid Malignancies

Phase 1

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Duarte, California1 trial

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.